With a biomedical cyclotron and the capability to synthesize a variety of imaging radiotracers, the Cyclotron and Radiochemistry Program is poised to integrate Positron Emission Tomography with human, translational, and preclinical research at UT Southwestern Medical Center.
The Cyclotron and Radiochemistry Program (CRP) will focus on the development of three classes of image probes:
- Radiotracers labeled with 18F (t½= 110 min)
- Radiotracers labeled with 15O, 13N, and 11C (t½ = 2 min, 10 min, and 20 min) that are chemically indistinguishable from their nonradioactive counterparts
- Macromolecules (e.g., antibodies and nanoconstructs) tagged with metal radioisotopes, such as 64Cu and 89Zr (t½ = 12.7 hours and 3.27 days)
The Program will particularly benefit these fields:
- Neurosciences: Neurodegenerative diseases, traumatic brain injury, cerebrovascular diseases, epilepsy, movement disorders, etc.
- Psychiatry: Psychosis, treatment-resistant depression, drug abuse, autism, ADHD, etc.
- Oncology: Cancer initiation, proliferation, and dissemination; treatment response; tumor microenvironment and phenotyping; etc.
- Cardiology: Coronary artery disease, myocardial ischemia, congestive heart failure, hypertrophy, complications of diabetes, etc.
- Metabolism: Intermediary metabolism of biomolecules (carbohydrates, lipids, nucleotides, amino acids, etc.)
- Biochemistry: Biomarker identification, drug discovery, pharmacokinetics of drugs, etc.
- Immunology: Autoimmune disease pathogenesis, immunotherapy, cancer immunology, etc.
- Innovative technologies: Nanomedicine, drug delivery, theranostics, etc.